Engram Cells: Part Two: The Same Result in Alzheimer Models

Abstract

Part One showed that a memory blocked by a protein synthesis inhibitor is still physically present and can be switched on with light. That is a striking laboratory result about an artificial amnesia.

In 2016 the same group asked whether the logic holds in a disease. In mice carrying mutations that model early Alzheimer's, before amyloid plaques appear, direct optogenetic activation of hippocampal engram cells retrieved a memory the animals could not otherwise recall.

They then went further and restored natural recall — by inducing long-term potentiation at the specific synapses feeding those cells. This part covers what that result does and does not mean.

1.The Model, and Why the Age Matters

The mice overexpress a variant of presenilin-1 together with the Swedish mutation of amyloid precursor protein — a standard model of familial Alzheimer's pathology.

The experiment turns on comparing two ages. At nine months the animals showed severe plaque deposition across multiple brain regions, including the dentate gyrus and medial entorhinal cortex. At seven months they had no amyloid plaques at all.

Behaviourally the two ages differ in a way that matters. Nine-month-old mice were impaired in both short-term memory at one hour and long-term memory at 24 hours, which indicates a problem with encoding — the memory was never properly formed.

Seven-month-old mice showed normal freezing during training and normal short-term memory at one hour, but were impaired at 24 hours. Something was formed and then became inaccessible.

That dissociation is what makes the younger group the interesting one, and it is a stage that precedes the pathology usually taken to define the disease.

2.The Memory Was There

Direct optogenetic activation of hippocampal engram cells produced memory retrieval in these mice, despite their being amnesic in long-term memory tests when natural recall cues were used.

The authors state the conclusion in the terms Part One established: this reveals a retrieval, rather than a storage, impairment.

The physical correlate was identified. The age-dependent amnesia correlated with a progressive reduction in dendritic spine density on dentate gyrus engram cells — the same structural feature that was missing from the amnesic engrams in Part One.

Two different causes of amnesia — a protein synthesis inhibitor and a genetic model of neurodegeneration — converging on the same lesion: an engram that exists, connected as it should be, but without the synaptic amplification that lets ordinary cues reach it.

3.Restoring Natural Recall

The next step is the one that distinguishes this paper from a demonstration.

Rather than driving the engram directly, the team induced long-term potentiation optogenetically at perforant path synapses — the inputs from entorhinal cortex onto dentate gyrus engram cells. This restored both spine density and long-term memory.

The animals could then remember without the light. The intervention repaired the access route rather than substituting for it.

And the control that makes the causal claim stick: ablating the dentate gyrus engram cells whose spine density had been restored prevented the rescue of long-term memory. The recovery depended on those specific cells, not on a general effect of stimulation.

The authors' proposal follows: selective rescue of spine density in engram cells may lead to an effective strategy for treating memory loss in early stages of Alzheimer's disease.

4.The Distance to a Treatment

That closing sentence contains the word may, and it is doing a great deal of work.

Every step of the rescue required optogenetics: viral delivery of a light-sensitive protein into specific neurons, genetic tagging during learning, and implanted fibres delivering patterned light to a defined pathway. There is no human equivalent, and the barrier is not incremental.

The model is also a genetic one. These mice carry mutations causing early-onset familial Alzheimer's, which accounts for a small minority of human cases. Most Alzheimer's disease is late-onset and not caused by these mutations, and mouse models of this type have an extensive record of producing rescues that did not transfer to people.

And the memory being rescued is a 24-hour contextual fear association. The memory loss that defines early Alzheimer's in a person is episodic, autobiographical and accumulates over years.

What the work establishes is a principle: at a stage before plaques, in this model, the information is still present and the deficit is in access. That is a genuinely different picture from progressive erasure, and it reframes what a treatment would have to do.

5.What Two Papers Leave

A memory is held in a specific, identifiable population of cells, and that population maintains its pattern of connections even when the behaviour it supports has disappeared.

Consolidation appears to build access rather than content. Both an acute pharmacological block and an early neurodegenerative process remove the same thing — synaptic strengthening and spine density — while leaving the trace.

Restoring that access restores natural recall, in mice, by a method available only in mice.

We should also record what we could not read. This topic was filed with four sources; the two review articles by Tonegawa and colleagues, in Neuron and Nature Reviews Neuroscience, have no PubMed Central deposit and no open copy we could obtain. Both parts here are written from the two primary papers, which we read in full.

Editorial Comment

MindHeaven® makes no claim relating to memory engrams, spine density, long-term potentiation or Alzheimer's disease, and no ingredient in our formulations has been shown to influence any of them.

This is the point in the library where the gap between mechanism and product is widest, and it is worth naming for that reason. Everything here — the trace, the access route, the rescue — was achieved by genetically modifying neurons and illuminating them through an implanted fibre. A capsule does not do a smaller version of that. It does nothing of the kind at all.

Alzheimer's disease and memory loss are medical matters. If memory changes are causing concern for you or someone close to you, assessment identifies causes that are treatable — thyroid function, B12 status, medication effects, depression, sleep apnoea — alongside those that are not. That is worth considerably more than anything on a supplement shelf, and it is a conversation for a doctor.